Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
UCB |
---|---|
Information provided by: | UCB |
ClinicalTrials.gov Identifier: | NCT00401830 |
This trial will investigate the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
Condition | Intervention | Phase |
---|---|---|
Fibromyalgia Syndrome |
Drug: Lacosamide Other: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome |
Enrollment: | 159 |
Study Start Date: | October 2006 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator |
Other: placebo
Matching placebo tablet administered twice daily
|
Lacosamide: Experimental
Lacosamide Tablet 400mg daily
|
Drug: Lacosamide
Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day to 400mg/day at weekly intervals of 100mg
|
This was a proof-of-concept study and not powered for statistical comparisons.
The trial consisted of a 4-week Titration Phase, an 8-week Maintenance Phase, a 1-week Taper Phase, and a 2-week Safety Follow-Up Phase. If subjects met the eligibility criteria, they were randomized to receive either lacosamide 400mg/day or placebo during the Maintenance Phase. Subjects assigned to lacosamide were titrated from 100mg/day to 400mg/day at weekly intervals of 100mg. All subjects who completed the 4-week Titration Phase entered an 8-week Maintenance Phase. No dose adjustment was allowed during the Maintenance Phase. The Treatment Phase was defined as the combined Titration and Maintenance Phases.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
Responsible Party: | UCB ( Study Director ) |
Study ID Numbers: | SP887 |
Study First Received: | November 9, 2006 |
Last Updated: | July 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00401830 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Fibromyagia Syndrome Lacosamide Vimpat Harkoseride |
Signs and Symptoms Muscular Diseases Neuromuscular Diseases Musculoskeletal Diseases |
Myofascial Pain Syndromes Fibromyalgia Pain Rheumatic Diseases |
Signs and Symptoms Pathologic Processes Disease Muscular Diseases Neuromuscular Diseases Musculoskeletal Diseases |
Myofascial Pain Syndromes Fibromyalgia Syndrome Nervous System Diseases Rheumatic Diseases |